DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
— - 2 Goldman Sachs - 2 IBM's Watsonx - 1 Kilroy - 1 Ron Insana - 1 Cory Kasimov - 1 Kasimov - 1 We've - 1
Top related locs:
California — Ceridian China OW U.S Tyler Van Buren Bengaluru
Top related orgs:
BridgeBio Pharma - 2 ISI - 2 Citi - 2 Marathon Oil - 1 ConocoPhillips - 1 Marathon - 1 iFi - 1 Kilroy Realty - 1

Search resuls for: "BridgeBio"


9 mentions found


☆ This AI model sees big upside for a bitcoin miner and several biotech stocks
  + stars: | 2024-06-02 | by ( Jesse Pound | In Jesse-Pound | ) www.cnbc.com   time to read: +2 min
An AI model that is trying to use machine learning to pick stocks is optimistic about the outlook for some names in volatile sectors over the next month. IFi AI is a company aimed at individual investors that identifies stocks with potential upside based on a blend of fundamental, technical and news data. The stock in the model's highest confidence bracket with the most projected upside is a similarly named company — Marathon Digital . But instead of being an energy company, Marathon Digital is a bitcoin miner. CNBC senior analyst and commentator Ron Insana is the CEO if iFi AI, which launched in March .
Persons: IBM's Watsonx, —, Kilroy, Ron Insana Organizations: Marathon Oil, ConocoPhillips, Marathon, iFi, Kilroy Realty, BridgeBio Pharma, Viking Therapeutics, Therapeutics, CNBC Locations: California
☆ Evercore ISI says three years of biotech underperformance may be ending, gives its 5 favorite stocks
  + stars: | 2024-05-14 | by ( Hakyung Kim | ) www.cnbc.com   time to read: +2 min
"After 3 years of painful underperformance, winter is finally thawing and spring just might be in the air," analyst Cory Kasimov wrote in a Monday note. Biotech stocks broadly peaked in early 2021 when interest rates were at a trough, Kasimov noted. While biotech stocks are sensitive to interest rates, the analyst believes most of the group's other catalysts — such as mergers and access to capital — remain "relatively consistent." XBI YTD mountain SPDR S & P Biotech ETF performance year to date The sector is opportune for investors looking for "a stock picker's market," according to Kasimov. With this in mind, he named seven stocks to his core initial list, which he named "The Magnificent Seven."
Persons: Cory Kasimov, Kasimov, We've, Neurocrine, — CNBC's Michael Bloom Organizations: ISI, Biotech, P Biotech, Moderna Locations: —
☆ Here are Tuesday's biggest analyst calls: Nvidia, Apple, Nike, TJX, Disney, Peloton, Re/Max, Home Depot and more
  + stars: | 2023-11-07 | by ( Michael Bloom | ) www.cnbc.com   time to read: +6 min
Morgan Stanley reiterates Apple as overweight Morgan Stanley said it's standing by its overweight rating on the stock after its 10-K annual report. Morgan Stanley initiated Tal Education as overweight Morgan Stanley said the China education company is defensive. Morgan Stanley names TotalEnergies a top pick Morgan Stanley named TotalEnergies a top pick and says the energy company has "resource depth and resilience." Morgan Stanley reiterates Tesla as overweight Morgan Stanley said in a note Tuesday that Tesla needs to "stop missing numbers" and execute better, but that the firm is sticking with its overweight rating. Morgan Stanley downgrades Re/Max to underweight from equal weight Morgan Stanley said in its downgrade of Re/Max that it sees too many negative catalysts for the real estate company.
Persons: Morgan Stanley, Apple, it's, Edward Jones, Hewlett Packard, PC's, D.A, Davidson, Appian, Wells, Wells Fargo, financials, Tal, EDU, TAL, TotalEnergies, TJX, Goldman Sachs, Tesla, Melius, Morgan Stanley downgrades, Max Organizations: RBC, Home, ISI, Nike, Athletic, UBS, Apple, Citi, Deutsche Bank, TAM, Hewlett, Disney, Tal Education, BP, TJX Companies, Thomson Reuters, Nasdaq, Tesla, Nvidia Locations: Ceridian, China, OW
☆ BridgeBio's heart disease drug meets late-stage study goal, shares soar
  + stars: | 2023-07-17 | by ( Khushi Mandowara | ) www.reuters.com   time to read: +2 min
July 17 (Reuters) - BridgeBio Pharma Inc's (BBIO.O) experimental drug for a rare heart disease showed significant improvement in patients in a late-stage study, sending its shares surging 65% on Monday. BridgeBio's drug improved survival by 81% in the study patients compared to 74% on the placebo, and also reduced frequency of heart disease-related hospitalization by 50%. The California-based company also provided additional data comparing it with Pfizer's drug. Acoramidis showed 92% improvement on heart failure test, compared to patients on placebo and Pfizer's drug at 30 months. The additional data suggests that BridgeBio's drug was better than tafamidis in controlling the disease, said TD Cowen analyst Tyler Van Buren.
Persons: acoramidis, Acoramidis, Cowen, Tyler Van, Luca Issi, BridgeBio, BridgeBio's, Khushi, Nivedita Bhattacharjee Organizations: BridgeBio Pharma, Alnylam Pharmaceuticals, Ionis Pharmaceutical, RBC Capital, U.S . Food, Drug Administration, Thomson Locations: U.S, California, Tyler Van Buren, Bengaluru
☆ Stocks making the biggest moves midday: Ford, AT&T, Yelp, Figs and more
  + stars: | 2023-07-17 | by ( Michelle Fox | ) www.cnbc.com   time to read: +4 min
Paramount Global — The entertainment company's stock shed 4.4% after the new "Mission: Impossible" movie underperformed expectations at the box office. The Wall Street firm said Progressive's valuation is now compelling after its poor results in June, and said the company has long-term earnings power and growth potential. Yeti — The cooler company's stock fell 5.8% following a downgrade to underweight from sector weight by KeyBanc. The Wall Street firm cited concerns over Yeti's growth and its heavy wholesale channel inventory. State Street — The asset manager slipped more than 3.1% after the firm was downgraded by multiple Wall Street firms, including JPMorgan.
Persons: Rivian, Tesla —, Knight, Yelp, Goldman Sachs, Raymond James, Cantor, —, Samantha Subin, Alex Harring, Tanaya Macheel, Brian Evans Organizations: Ford —, Ford, Tesla — Elon, Constellation Software, Intercontinental Exchange, Citi, BridgeBio Pharma —, Activision, Microsoft, Sony, PlayStation, Activision Blizzard, Paramount Global, Variety, Apellis Pharmaceuticals, American, JPMorgan, Wall, State Street's, Iris Energy
☆ Here are Wednesday's biggest analyst calls: Netflix, Apple, Tesla, Amazon, Bowlero, Exxon & more
  + stars: | 2023-04-19 | by ( Michael Bloom | ) www.cnbc.com   time to read: +8 min
UBS upgrades Exxon to buy from neutral UBS said in its upgrade of the oil and gas giant that it likes the company's balance sheet. Bank of America reiterates Meta as buy Bank of America says it likes "self-help stocks in an uncertain macro." Bank of America reiterates Nvidia as buy Bank of America raised its price target on the AI beneficiary to $340 per share from $310. Bank of America downgrades CDW to neutral from buy Bank of America downgraded the technology products company after its disappointing earnings report on Tuesday. Wolfe reiterates Amazon as outperform Wolfe says it's standing by its outperform rating on the stock heading into earnings next week. "
Organizations: ~$
☆ Bridgebio shares surge on takeout target hopes
  + stars: | 2023-03-29 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBridgebio shares surge on takeout target hopesCNBC's Meg Tirrell joins 'Power Lunch' to report on Bridgebio's stock surge and pharma returns.
☆ Stocks making the biggest moves midday: Snap, Apple, Boeing and more
  + stars: | 2023-03-06 | by ( Hakyung Kim | ) www.cnbc.com   time to read: +2 min
Apple — Shares advanced more than 3% after Goldman Sachs initiated coverage of the big technology stock as a buy. Credit Suisse — Shares were down about 1% after former top shareholder Harris Associates sold its entire stake in Credit Suisse, according to a Financial Times report. The Wall Street firm said the luxury housing market is struggling to stabilize, which will impact RH's business. The Wall Street firm said the derating of Emerson Electric is overdone. Domino's Pizza — Domino's Pizza shares advanced more than 4%.
☆ Private equity acquires a taste for drug development
  + stars: | 2023-01-09 | by ( David Carnevali | ) www.reuters.com   time to read: +6 min
Jan 9 (Reuters) - Private equity firms that deemed drug development too risky for their liking in the past are increasingly investing in the sector, raising dedicated funds and coming up with deals that compensate them for the uncertainty involved. These deals are not structured as the leveraged buyouts that private equity firms are mostly known for. In most cases, the drug makers start paying the money back to the private equity firms when the drug is being developed, either by issuing equity, tapping cash on hand or borrowing. They also share a slice of the newly developed drug's revenue with the private equity firms once it's approved. Private equity firms also provide capital to spin out drugs into new companies.
0 next >>
Total: 9